Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

San Diego Convention Center

Jun 15, 2014 8:30 AM - Jun 19, 2014 12:45 PM

111 W Harbor Drive, , San Diego, CA 92101 , USA

DIA 2014 50th Annual Meeting "Celebrate the Past - Invent the Future"

Stage Gate Decision-Making Workshop (Part 2 of 2)

Session Chair(s)

Courtland R. LaVallee, MBA

Courtland R. LaVallee, MBA

Executive Director, Project Management

Dynavax Technologies, United States

This interactive two-part workshop will help attendees who may be primarily involved in tactical activities understand how a company makes strategic decisions for moving a product forward. After a review of a new drug product, attendees will work in teams to discuss their product’s information and make recommendations for whether and how their product should be advanced through the development pipeline.

Workshop content is based on DIA's New Drug Product Development and Life Cycle Management training course. Part 1 of this workshop will focus on processes and decisions in phase 2, while Part 2 will focus on phase 3 and the decision to file.

Preregistration is required, and attendees are strongly encouraged to attend both Part 1 and Part 2.

Part 1 will take place on Monday at 8:30 am (Session #104).

To secure a seat for this specific workshop, please email annualmeetingprogram@diahome.org, Subject line: Stage Gate Decision-Making Workshop.

**Due to workshop format, seating will be limited.

The San Diego Convention Center has stringent regulations on maximum room capacities, and they are strictly enforced. Once all seats are occupied, DIA will be required to close the workshop, and no more participants will be admitted. Interested attendees are encouraged to arrive at workshops early in order to ensure seating. Please note, as a workshop with interactivity, this event will not be recorded.

Learning Objective : Describe the process and considerations that factor into deciding to advance a compound from phase 2 into phase 3; Describe the factors influencing a decision to file for a new drug application (NDA).

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.